Delving into the Latest Updates on Lipum AB with Synapse

概览

疾病领域	数量

免疫系统疾病	1

排名前五的药物类型	数量

单克隆抗体	1

排名前五的靶点	数量

CEL(carboxyl ester lipase)	1

关联

1

项与 Lipum AB 相关的药物

SOL-116

靶点

CEL

作用机制

CEL抑制剂

在研机构

Flerie AB [+2]

原研机构

Lipum AB

在研适应症

类风湿关节炎

非在研适应症-

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期-

2

项与 Lipum AB 相关的临床试验

NL-OMON56208 / RecruitingN/A

A randomized, double-blind, placebo-controlled, first-in-human phase 1 study evaluating safety, tolerability, and pharmacokinetics of single ascending doses of SOL-116 (a humanized monoclonal anti-BSSL antibody) in healthy subjects and patients with rheumatoid arthritis. - CS0382-210463

开始日期2022-10-21

申办/合作机构

Lipum AB

NCT05576012 / Active, not recruiting临床1期

A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase I Study Evaluating Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of SOL-116 in Healthy Subjects and Patients With Rheumatoid Arthritis

This is a randomized, double-blind, placebo-controlled, first-in-human phase I study. It consists of a single ascending dose part in healthy subjects (Part 1) and in patients with rheumatoid arthritis (Part 2) as well as a multiple dose part in healthy subjects (Part 3). The study will collect information on pharmacokinetics, safety and tolerability.

开始日期2022-10-13

申办/合作机构

Lipum AB

[+1]

100 项与 Lipum AB 相关的临床结果

登录后查看更多信息

0 项与 Lipum AB 相关的专利（医药）

登录后查看更多信息

100 项与 Lipum AB 相关的药物交易

登录后查看更多信息

100 项与 Lipum AB 相关的转化医学

登录后查看更多信息